BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Science '22 in Review
Top Biopharma Trends of 2022
Top Med-tech Trends of 2022
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, December 1, 2023
See today's BioWorld
Home
» High priced cancer drugs not translating into lofty revenue
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
High priced cancer drugs not translating into lofty revenue
May 12, 2014
By
Brian Orelli
No Comments
The average cost per month for a branded oncology drug treatment in the U.S. is about $10,000, around double where it was a decade ago, according to a new report by IMS Institute for Healthcare Informatics.
BioWorld